MBC Advocate· @MBCadvocate · X·· 2026-04-21Score60
Reading
Next-generation ADCs: payload innovation
AVA6103 / pan-RAS ADC · Tricomplex pan-RAS as payload
Body
Congrats Avacta! This is fantastic news!
Metastatic ER+ breast cancer is included, with expansion cohorts for AVA6103 planned in additional FAP+ cancers, including hormone receptor–positive breast cancer (HR+ BC). #AVCT #AACR26
Heat 56 · 46 likes · 1 reply · 9 reposts
Conference abstracts
5846matched by 代号 AVA6103
AVA6103 is a FAP-enabled pre|CISION®peptide-drug conjugate delivering sustained release of exatecan in the tumor microenvironment with potent antitumor activityCurtis Rink, Tom Clough, Ellen Watts, Folake Orafidiya, Marine Houée, Sophie Brown, Victoria Juskaite, Gezim Lahu, Ruairidh Edwards, Karen Campbell, Dave Liebowitz, David Jones, Francis Wilson, Michelle Morrow
Read the abstract →Source: MBC Advocate · x.com